Alloy Therapeutics
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.
$40MSeries E
Role not disclosedG
Gaingels
Activity from announced rounds
Activity in this selectionSeries C+
Gaingels co-invests alongside venture leads in companies committed to diverse and inclusive teams, spanning seed through growth and pre-IPO rounds across technology, healthcare and consumer markets.
Its investor community includes LGBTQ+ people and allies, extending representation within the ownership of venture-backed companies. Portfolio companies work with its Gaingels Letter commitments and Venture Inclusion programme on building more inclusive organisations.
A board access programme provides free recruitment advice for diverse board members and observers. This gives founders a practical governance resource alongside a co-investment partner for a round led by another venture firm.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $40M 1 disclosed · full round size, not this investor’s share